You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Details for Patent: RE48468

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE48468 protect, and when does it expire?

Patent RE48468 protects EXONDYS 51 and is included in one NDA.

This patent has seventy-four patent family members in seventeen countries.

Summary for Patent: RE48468

Title:	Means and methods for counteracting muscle disorders
Abstract:	The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
Inventor(s):	De Kimpe; Josephus Johannes (Utrecht, NL), Platenburg; Gerard Johannes (Voorschoten, NL), Van Deutekom; Judith Christina Theodora (Dordrecht, NL), Aartsma-Rus; Annemieke (Hoofddorp, NL), Van Ommen; Garrit-Jan Boudewijn (Amsterdam, NL)
Assignee:	BioMarin Technologies B.V. (Leiden, NL) Academisch Ziekenhuis Leiden (Leiden, NL)
Application Number:	15/881,574
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Delivery; Device;

Drugs Protected by US Patent RE48468

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING	⤷ Try a Trial
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE48468

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07119351	Oct 26, 2007

International Family Members for US Patent RE48468

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008317566	⤷ Try a Trial
Australia	2009310557	⤷ Try a Trial
Australia	2009310558	⤷ Try a Trial
Canada	2704049	⤷ Try a Trial
Canada	2741629	⤷ Try a Trial
Canada	2741793	⤷ Try a Trial
Canada	3017539	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.